Ignite Creation Date:
2024-05-06 @ 6:23 PM
Last Modification Date:
2024-10-26 @ 2:47 PM
Study NCT ID:
NCT05649748
Status:
RECRUITING
Last Update Posted:
2024-07-15
First Post:
2022-12-06
Brief Title:
An Extension Study of Treprostinil Palmitil Inhalation Powder TPIP for Pulmonary Arterial Hypertension PAH
Sponsor:
Insmed Incorporated
Organization:
Insmed Incorporated
Study Overview
Official Title:
An Open-Label Extension Study to Assess the Safety Tolerability and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of the study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PAH from studies INS1009-201 NCT04791514 INS1009-202 NCT05147805 and other lead-in studies of TPIP in participants with PAH
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2023-505539-11-00 | OTHER | EU CT Number | None |
| 2022-001951-18 | EUDRACT_NUMBER | None | None |